Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 19/20 | 0.86 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.49 |
| ▸ | RIPK2 | O43353 | 2/20 | 0.49 |
| ▸ | ACVR1B | P36896 | 2/20 | 0.49 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.41 |
| ▸ | PRKD3 | O94806 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 1/20 | 0.41 |
| ▸ | HPGD | P15428 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.41 |
| ▸ | CSNK1A1 | P48729 | 1/20 | 0.41 |
| ▸ | CSNK1D | P48730 | 1/20 | 0.41 |
| ▸ | CSNK1E | P49674 | 1/20 | 0.41 |
| ▸ | RPS6KA1 | Q15418 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30194941 | 1.00 | TGFBR1 (0.86) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL29504100 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4339710 | 0.93 | TGFBR1 (1.00) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL375627 | 0.92 | TGFBR1 (0.73) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL15678349 | 0.92 | TGFBR1 (0.73) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4347711 | 0.89 | TGFBR1 (0.70) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL4337372 | 0.89 | TGFBR1 (0.69) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL375120 | 0.89 | TGFBR1 (0.69) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL19442173 | 0.85 | TGFBR1 (0.64) | TGFBR1MAPK14RIPK2ACVR1BTDP1 | |
| SCHEMBL18604427 | 0.85 | TGFBR1 (0.62) | TGFBR1MAPK14RIPK2ACVR1BTDP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 54 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20160310645-A1 | Compositions and Methods for Treating and Preventing Neointimal Stenosis | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-10-27 | — | — | US | claimed |
| US-9446175-B2 | Compositions and methods for treating and preventing neointimal stenosis | YALE UNIVERSITY (US) | 2016-09-20 | — | — | US | claimed |
| US-20140348889-A1 | Compositions and Methods for Treating and Preventing Neointimal Stenosis | YALE UNIVERSITY (US) | 2014-11-27 | — | — | US | claimed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | claimed |
| US-20240124842-A1 | CELL PREPARATION METHOD | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2024-04-18 | — | — | US | disclosed |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2024-03-14 | — | — | US | disclosed |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2024-01-02 | — | — | US | disclosed |
| US-11851681-B2 | Cell preparation method | KYOTO PREFECTURAL PUBLIC UNIVERSITY CORPORATION (JP) | 2023-12-26 | — | — | US | disclosed |
| US-11401510-B2 | Generation of airway basal stem cells from human pluripotent stem cells | TRUSTEES OF BOSTON UNIVERSITY (US) | 2022-08-02 | — | — | US | disclosed |
| US-20220177978-A1 | METHODS OF PREDICTING AND PREVENTING CANCER IN PATIENTS HAVING PREMALIGNANT LESIONS | TRUSTEES OF BOSTON UNIVERSITY | 2022-06-09 | — | — | US | disclosed |
| EP-3947737-A2 | METHODS OF PREDICTING AND PREVENTING CANCER IN PATIENTS HAVING PREMALIGNANT LESIONS | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2022-02-09 | — | — | EP | disclosed |
| US-20140328860-A1 | METHODS FOR STIMULATING HEMATOPOIETIC RECOVERY BY INHIBITING TGF BETA SIGNALING | CORNELL UNIVERSITY (US) | 2014-11-06 | — | — | US | disclosed |
| US-8871744-B2 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partyers, LLC (US) | 2014-10-28 | — | — | US | disclosed |
| US-20140127228-A1 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20140127228-A1 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER | Indiana University School of Medicine (US) | 2014-05-08 | — | — | US | disclosed |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B&G PARTNERS, LLC | 2012-01-26 | — | — | US | disclosed |
| EP-2409708-A1 | Compounds and methods for selectively targeting tumor-associated mucins | B & G Partners, LLC (US) | 2012-01-25 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140127228-A1 | INHIBITION OF TGFBETA SIGNALING TO IMPROVE MUSCLE FUNCTION IN CANCER | MUSK, TGFBR1, TGFBR2 | TGFBR1 2/4885MAPK14 1509/4885RIPK2 1532/4885 |
| US-11857575-B2 | Mesenchymal stem cell-derived exosomes and their uses | EXOSC9, EXOSC5, EXOSC10 | TGFBR1 2539/4885MAPK14 3026/4885RIPK2 798/4885 |
| US-20240084258-A1 | METHOD FOR PREPARING BROWN ADIPOCYTE | FABP4, MAPK1, MAP3K1 | TGFBR1 304/4885MAPK14 40/4885RIPK2 1254/4885 |
| US-20120022016-A1 | Compounds and methods for selectively targeting tumor-associated mucins | MUC1, NEU4, ALK | TGFBR1 1324/4885MAPK14 2025/4885RIPK2 2625/4885 |
| US-20140328860-A1 | METHODS FOR STIMULATING HEMATOPOIETIC RECOVERY BY INHIBITING TGF BETA SIGNALING | HCLS1, MCL1, CSF3R | TGFBR1 8/4885MAPK14 487/4885RIPK2 2195/4885 |
| US-20140128349-A1 | ADMINISTERING INHIBITORS OF TGFBETA SIGNALING IN COMBINATION WITH BENZOTHIAZEPINE DERIVATIVES TO IMPROVE MUSCLE FUNCTION IN CANCER PATIENTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885MAPK14 1802/4885RIPK2 1516/4885 |
| US-11401510-B2 | Generation of airway basal stem cells from human pluripotent stem cells | KRT18, CFTR, MCOLN3 | TGFBR1 591/4885MAPK14 4703/4885RIPK2 4557/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.